Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative AI–driven drug discovery company, today announced promising first-in-human Phase 1 data for ISM6331, its investigational oral pan-TEAD inhibitor designed using Chemistry42 generative AI platform. Among response-evaluable participants with mesothelioma, the results showed a 40.0% objective response rate (ORR) at 130 mg once daily and an 18.2% ORR with a 68.2% disease control rate (DCR) across the dose cohorts. Findings were presented as a Rapid Oral at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid by Melina E. Marmarelis, MD of Abramson Cancer Center, University of Pennsylvania).

Artificial intelligence can make a scammer sound like your boss, your bank or even someone you love. And as the technology becomes more sophisticated, a University of Missouri cybersecurity expert says spotting a scam isn’t as simple as looking for spelling mistakes.

Prasad Calyam, a Curators’ Distinguished Professor in Mizzou’s College of Engineering and director of the Artificial Intelligence Education, Research and Infrastructure Center (Mizzou AERI), explains how AI is changing online security, what information people should keep private and what steps they can take to recognize scams and protect their accounts.

KAIST, DGIST, KBRI, and KRIBB develop an implantable neural chip integrating neurotransmitter sensing, light stimulation, and wireless monitoring.

Changes in a neurotransmitter involved in memory and learning observed in miniature pig brains following drug administration.

This technology could support neural interface research, from assessing drug action to adjusting stimulation based on the brain’s response.